NVILE forecast ·

Novo Nordisk (NVO) Stock Forecast: Next 30 Days

Over the next 30 days, the calibrated 80% range for NVO is $35.52 to $46.66. Q3 earnings on 2026-11-04 is the primary near-term swing catalyst, with a typical single-session earnings move of 3.8%. Options traders imply a 6.3% earnings move, while the model assigns a 6% chance of a single-day earnings move exceeding 10%. Over the 30-day window, there is a 20% probability of rising over 10% and a 15% probability of falling over 10%.

Price now

$40.46

Nov 3, 2026

In 30 days

$40.71

NVILE forecast

Expected move

+0.6%

Range

$35.52–$46.66

$51.40$43.56$35.72Jun 29, 2026Today+30d

What to do

  • Size positions conservatively within the $35.52 to $46.66 range rather than treating $40.71 as an expected target.Calibrated distributions indicate a wide 80% range with balanced two-sided tail risks over 30 days.
  • Manage discrete volatility ahead of the 2026-11-04 earnings report.[12]Implied volatility prices a 6.3% move, while recent historical earnings sessions average a 3.8% shift.
  • Monitor post-earnings margin disclosures and U.S. oral GLP-1 prescription volumes for guidance shifts.[5],[7],[11]Analyst revisions and competitive launches by Eli Lilly remain the decisive fundamental drivers.

Why

  • NVO trades at $40.46 with an 80% 30-day calibrated distribution of $35.52 to $46.66 ahead of Q3 results on 2026-11-04.[12]
  • Consensus 12-month target averages $45.07 (range $39.72-$61.75), while current-quarter EPS estimates fell 9.6% over the last 30 days.[5]
  • FINRA Reg SHO daily short-sale volume share rose to 45.7% (5-day average 44.6% vs 20-day 41.5%), signalling elevated hedging and selling interest.[2]
  • Oral Wegovy pill adoption has exceeded five million U.S. prescriptions within roughly 30 weeks of launch, expanding to Europe and the UAE.[11],[12]
  • Escalating GLP-1 competition from Eli Lilly's Mounjaro, Zepbound, and oral pill Foundayo exerts pricing and market share pressure.[7],[11]

What could go wrong

  • Options pricing implies a 6.3% earnings move, with a 15% probability of a 30-day drawdown exceeding 10%.
  • Margin contraction and patent expiration concerns triggered broker downgrades and lowered price targets.[4],[9]
  • Elevated FINRA short-sale volume share at 45.7% signals rising pre-earnings hedging pressure.[2]

How it connects

  • Novo Nordisk A/Smanufactures and commercializesWegovy Pill[6],[12]
  • Eli Lilly and Companycompetes in obesity and GLP-1 therapy marketsNovo Nordisk A/S[7],[11]
  • Eli Lilly and Companydeveloped and launched in U.S. in April 2026Foundayo[11]
  • Citigroupcut price target to DKK 296 from DKK 310Novo Nordisk A/S[9]
  • TD Cowendowngraded on semaglutide patent loss concernsNovo Nordisk A/S[4]
  • Mike Doustdarserves as Chief Executive OfficerNovo Nordisk A/S[8],[11]
  • Eli Lilly and Companycollaborates with in EuropeAlmirall, S.A.[10]

NVILE's track record on this page

MadeForecastActualResult
Nov 3, 2026$40.71Due Dec 3, 2026Pending

Every published call is scored when it comes due. See all results →

Sources

  1. 1.NOVO NORDISK A S 20-F (2026-02-04) · sec.gov
  2. 2.NVO daily short-sale volume (FINRA) · finra.org
  3. 3.NOVO NORDISK A S insider transactions (SEC Form 4) · sec.gov
  4. 4.TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook · cnbc.com
  5. 5.NVO Wall Street consensus: estimates, revisions, ratings, targets · finance.yahoo.com
  6. 6.Novo Nordisk Earnings Call: Growth Engine Meets 2026 Reset · theglobeandmail.com
  7. 7.Can Novo Nordisk (NYSE:NVO) Trade Below Fair Value On Earnings? · finance.yahoo.com
  8. 8.Novo Nordisk's stock tumbles as doubts persist about Ozempic maker's strategy · morningstar.com
  9. 9.Citi cuts Novo Nordisk price target to DKK 296 on limited margin growth outlook · msn.com
  10. 10.ELI LILLY & Co 10-K (2026-02-12) · sec.gov
  11. 11.Wegovy pill sales smash forecasts, sending Novo Nordisk stock higher · cnbc.com
  12. 12.Novo Before Q3 Earnings: How Should Investors Play the Stock? · finance.yahoo.com

Questions

What is the Novo Nordisk forecast for the next 30 days?

NVILE's models put Novo Nordisk at about $40.71 in 30 days, +0.6% from $40.46. Over the next 30 days, the calibrated 80% range for NVO is $35.52 to $46.66. Q3 earnings on 2026-11-04 is the primary near-term swing catalyst, with a typical single-session earnings move of 3.8%. Options traders imply a 6.3% earnings move, while the model assigns a 6% chance of a single-day earnings move exceeding 10%. Over the 30-day window, there is a 20% probability of rising over 10% and a 15% probability of falling over 10%.

What price range does NVILE expect for Novo Nordisk?

The forecast range is $35.52 to $46.66 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.

What could change the Novo Nordisk outlook?

Options pricing implies a 6.3% earnings move, with a 15% probability of a 30-day drawdown exceeding 10%. Margin contraction and patent expiration concerns triggered broker downgrades and lowered price targets. Elevated FINRA short-sale volume share at 45.7% signals rising pre-earnings hedging pressure.

What should investors watch or do about Novo Nordisk?

Size positions conservatively within the $35.52 to $46.66 range rather than treating $40.71 as an expected target. Manage discrete volatility ahead of the 2026-11-04 earnings report. Monitor post-earnings margin disclosures and U.S. oral GLP-1 prescription volumes for guidance shifts.

How accurate are NVILE forecasts?

Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.

This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.